Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| fck001 | Registry Identifier | ZLiang |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Shenzhen Huada Genomics Co., Ltd. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies. In recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising.
The key to gynecologic malignancies is how to early diagnose and treat. With the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. Genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. Therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| experiment group | patients with cervical cancer, endometrial cancers or ovary cancer | ||
| control group | postmenopausal women with benign tumor |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Gene mutation from species of cervical cancer, endometrial cancers and ovary cancer | We expect to found spcific DNA mutation in the species (peripheral blood, liquid Pap smear and cancer tissue) from cervical cancer, endometrial cancers and ovary. | 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| the difference between detection sensitivity | Comparing sensiitivity of the three kinds of samples on early detection of gynecologic malignancies | 4 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
The experiment group are patients with cervical cancer, ovarian cancer or endometrial cancer.While the control group are volunteers on the basis of informed consent.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Obstetrics and Gynaecology, Southwest Hospital, Third Military | Chongqing | Chongqing Municipality | 400038 | China |
Not provided
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| D010051 | Ovarian Neoplasms |
| D016889 | Endometrial Neoplasms |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
The sample of blood, urine, cervical exfoliated cells and cancer tissue of patient should be used only in this research with informed consent. The remaining part will be Safekeeping.All information is strictly confidential.
| D009369 |
| Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D004701 | Endocrine Gland Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |